Boston, Massachusetts, August 5, 2026
Galibra Neuroscience has received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration for its investigational gene therapy targeting succinic semialdehyde dehydrogenase (SSADH) deficiency, marking an important regulatory milestone for a program designed to address the underlying cause of this ultra-rare inherited neurometabolic disorder. SSADH deficiency disrupts normal gamma-aminobutyric acid (GABA) metabolism and is associated with intellectual disability, epilepsy, autism spectrum disorder and a range of neurological and psychiatric manifestations. The disorder results from pathogenic variants in the ALDH5A1 gene, which interfere with normal GABA metabolism and cause accumulation of neuroactive metabolites. Currently, there are no FDA-approved disease-modifying therapies specifically for SSADH deficiency, with available treatment primarily focused on managing individual symptoms. Galibra is developing its investigational gene replacement approach with the goal of addressing the genetic basis of the disease.
Dual FDA Designations Support Rare Disease Development
The receipt of Orphan Drug and Rare Pediatric Disease designations provides Galibra with regulatory recognition of the rarity and seriousness of SSADH deficiency while potentially offering incentives as development progresses. FDA Orphan Drug Designation is available for drugs and biologics intended to treat rare diseases and can provide benefits including certain development incentives, potential waiver of specified FDA application fees and, following approval and satisfaction of applicable requirements, seven years of orphan drug exclusivity for the designated indication. Rare Pediatric Disease Designation applies to products being developed for serious or life-threatening rare conditions that primarily affect children. Subject to FDA approval and applicable statutory requirements and timelines, Galibra could potentially become eligible for a Rare Pediatric Disease Priority Review Voucher. Importantly, these designations do not represent marketing approval and do not establish the safety or efficacy of Galibra’s investigational therapy.
Gene Therapy Targets the Underlying ALDH5A1 Defect
Galibra’s program is being developed as a gene replacement therapy intended to address the underlying biology of SSADH deficiency, rather than solely treating its neurological manifestations. The company said development is supported by preclinical data generated at Boston Children’s Hospital and Harvard Medical School and that the candidate is on track to become the first gene replacement therapy specifically designed for SSADH deficiency. Galibra is currently conducting IND-enabling activities, an important collection of preclinical, manufacturing and regulatory work required before seeking authorization to begin human clinical testing. The company continues to collaborate with academic researchers and patient advocacy organizations as it works toward potential first-in-human studies. Its development program has also involved the SSADH Association and international patient community, which have supported natural history research, patient engagement and therapeutic development. Aurelix Bio is providing strategic clinical development, translational medicine, regulatory planning and operational support as the program advances toward the clinic.
Advertisement
Galibra Moves SSADH Gene Therapy Toward Clinical Development
The regulatory milestone is particularly significant because SSADH deficiency has substantial unmet medical need and lacks a disease-modifying treatment. By restoring functional genetic activity, gene replacement strategies could potentially intervene closer to the biological origin of inherited disorders, although Galibra’s approach remains investigational and must undergo clinical evaluation to establish safety and therapeutic benefit. The company’s immediate focus will be completing the necessary IND-enabling work and preparing its development program for potential clinical trials. Collaboration with patient organizations may also be important for defining disease progression, selecting meaningful clinical endpoints and identifying patients for future studies in such an ultra-rare population. The combination of FDA ODD and RPDD status, supporting preclinical research and ongoing IND-enabling activities places Galibra’s SSADH program at an important translational stage between laboratory development and potential human testing. For the broader rare neurological disease field, the program also reflects continued momentum toward genetic medicines designed to address disease mechanisms rather than relying exclusively on lifelong symptomatic management. If successfully translated into clinical development, Galibra’s candidate could provide an important opportunity to evaluate a first-in-class disease-modifying gene therapy approach for SSADH deficiency.
Source: Galibra Neuroscience press release
